Trial Profile
Safety, Tolerability and Pharmacokinetics of Multiple Escalating Doses of ORM-12741.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Aug 2010
Price :
$35
*
At a glance
- Drugs ORM 12741 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- 20 Aug 2010 Actual patient number is 49 according to ClinicalTrials.gov.
- 13 Aug 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 20 Feb 2010 New trial record